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There are increasing evidences that interaction of 
antibodies with antigens can lead to degradation of an-
tigens. Antibodies (Ab) possessing catalytic activity have 
been named catalytically active antibodies or abzymes 
[1]. Abzymes were detected in human organism during 
a variety of pathological conditions, such as systemic lupus 
erythematosus (SLE), autoimmune thyroiditis, asthma, 
multiple sclerosis, etc [1, 2]. Peptides, proteins, nucleic 
acids, and oligosaccharides can serve as substrates for 
catalytically active antibodies in human and other mam-
mals [3, 4]. Since abzyme’s target molecules were identi-
fied as autoantigens (i. e., DNA, thyroglobulin, vasoactive 
intestinal peptide), the involvement of abzymes in patholo-
gy of autoimmune disorders has been clearly documented 
[1–4]. Catalytically active autoantibodies typically found 
in humans with autoimmune disorders, have also been 
detected in cancer patients. DNA-hydrolyzing activity of 
IgG auto-ABs from sera of patients with various types of 
lymphoproliferative diseases was described [5, 6]. Tests 
for abzymes presence in patients with hematological 
tumors and SLE revealed the linkage of anti-DNA Ab 
catalysis with mature B-cell tumors, and increased pro-
bability of DNA-abzymes formation on the background of 
autoimmune conditions [1]. These data suggest possible 
similarity between the mechanisms of abzyme formation 
at SLE and B-cell lymphomas. Peptide-hydrolyzing and 
DNA-hydrolyzing activities of Bence Jones proteins from 
blood serum of myeloma patients are also well studied [7, 
8]. There are numerous data demonstrating that catalytic 
activity of anti-DNA IgGs and Bence Jones proteins is as-
sociated with their cytotoxic activity and correlates with 
the pathogenesis of the disease [9–13]. 
These data suggest that abzymes can play an 
important physiological role at autoimmune and on-
cological diseases. Therefore, their further studies are 
needed for better understanding of humoral immunity 
functions under normal and pathological conditions.
Recently, we have discovered a novel abzyme 
possessing histone H1 cleaving activity. It was demon-
strated that IgGs isolated by affinity chromatography 
from blood serum of patients with multiple sclerosis 
and sIgAs isolated from colostrums of healthy woman 
possesses the ability to cleave histone H1 of calf 
thymus, but not cleave core histones, bovine serum 
albumin and chicken egg lysozyme [14]. Here we show 
that histone H1-hydrolysing IgGs are present in blood 
serum of some patients with multiple myeloma. 
MATERIALS AND METHODS
Patients. Peripheral blood serum samples of 
11 patients (35–55-year old; men and women) dia-
gnosed with multiple myeloma were analyzed. An 
informed consent was obtained from all patients as 
it was approved by the Review Board of the Institute 
of Blood Pathology and Transfusion Medicine AMS 
of Ukraine in accordance with the regulations of the 
Ministry of Health Protection of Ukraine. 
Isolation of immunoglobulins (Igs). Igs were 
obtained from blood serum of patients with multiple 
myeloma by 3-fold precipitation of serum proteins 
by ammonium sulfate (50% saturation). The pellet 
was dissolved in 20 mM Tris-HCl buffer, pH 7.5, and 
dialyzed against the same buffer for 18 h. Igs concen-
tration was determined with the use of NanoDrop ND 
1000 spectrophotometer (NanoDrop Technologies, 
USA). Preparations of Igs were analyzed by electropho-
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resis in 12% PAGE in the presence of 0.1% SDS [15]. 
The gels were stained with Coomassie G 250. 
Purification of antibodies with affinity to histone 
H1 (anti-hisH1 Ab). Anti-hisH1 Abs were isolated 
from two catalytically active preparations of Igs on 
a column with hisH1-Sepharose as described in [14]. 
That was done by placing 2–2.5 mg Igs onto a column 
with histone H1-Sepharose (1 ml) equilibrated with TBS 
(140 mM NaCl, 20 mM Tris-HCl, pH 7.5). The column 
was washed with TBS, and anti-hisH1 Abs were eluted 
with 1 M NaCl. Fractions of anti-hisH1 Abs were dialyzed 
against 100 mM NaCl, 20 mM Tris-HCl, pH 7.5, for 18 h 
and analyzed by electrophoresis in 12% SDS-PAGE. 
Gel exclusion chromatography of Ab at conditions 
of dissociation of immune complexes (pH shock). 
The preparation of anti-hisH1 Ab capable of hydrolyzing 
histone H1 was precipitated with 50% ammonium sulfate. 
The pellet was dissolved in 0.1 M glycine-HCl (pH 2.6) and 
separated by gel filtration on a Toyopearl TSK HW55 co-
lumn (180 x 5 mm) in the same buffer. Chromatographic 
fractions (300 µl) were collected, neutralized with 1.5 M 
Tris-HCl, pH 8.8, dialyzed against buffer A for 18 h, and 
analyzed by electrophoresis in a gradient (7–18.5%) 
PAGE in the presence of 0.1% SDS.
Histone H1 isolation. Total histones of calf thymus 
were kindly provided by Dr. M.D. Lutsik, and histone 
H1 was purified from that preparation as described in 
[19]. Total histones were diluted in distilled water and 
core histones were precipitated with 4% perchloric 
acid. After centrifugation, hisH1 was precipitated from 
supernatant by 30% TCA. Then histone H1 was addi-
tionally purified by chromatography on CM-Sephadex 
according to [16]. Histone H1 preparations were ana-
lyzed by SDS-PAGE (15%). 
Proteolytic activity assays. We used two prepara-
tions containing calf thymus hisH1 and total histones 
fraction as substrate for proteolytic activity assays. The 
proteolytic reaction was performed in buffer (20 mM 
Tris-HCl, pH 7.5, and 0.1 M NaCl) in the presence of 
0.3 mg/ml histone H1 and 0.05–0.3 mg/ml antibo-
dies for 1 h at 37 °C. To analyze proteolytic activity of 
the chromatographic fractions, aliquots (30 µl) were 
supplemented with 6 µg hisH1, and mixtures were in-
cubated for 3 h at 37 °C. The reaction was stopped by 
addition of 4-fold amount of denaturing buffer (0.26 M 
Tris-HCl, pH 6.8, 4% SDS, 8% 2-mercaptoethanol, 40% 
glycerol), and the reaction products were separated by 
electrophoresis in 12% PAGE in the presence of 0.1% 
SDS. The gels were stained with Coomassie G 250. 
Cell proliferation study by MTS assay. The 
me thod was described in [17]. MTS (3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium was used in the assay 
(Promega Co., USA). Human leukemia T-cells of CEM 
line were obtained from Cell Collection at the Institute 
of Experimental Pathology, Oncology and Radiobiolo gy, 
National Academy of Sciences of Ukraine (Kyiv, Ukraine). 
Cells were maintained in RPMI-1640 medium (Sigma 
Chemical Co., USA) supplemented with 10% fetal bo-
vine serum (Sigma) and gentamycin (50 mg/ml, Sigma). 
Cells were cultured in a humidiﬁed atmosphere at 37 °C 
and 5% CO2. They were seeded into 96-well plate at 
starting concentration of 50 000 cells/ml, and 20 µg/ml 
of Ab was added and incubated for 24 h, 48 h and 72 h. 
10 µl of MTS/PMS solution (2 mg/ml / 0.92 mg/ml, 
ratio 1 : 20) was added to each well and the plate was 
incubated for 1 h at 37 °C in a humidiﬁed atmosphere 
with 5% CO2. Then the amount of soluble formazan 
produced by cell reduction of the MTS was measured 
according to the absorbance at 490 nm / 630 nm on 
the Microplate analyzer (BioTek, USA).
RESULTS 
Analysis of proteolytic activity of Abs. Antibody 
preparations were isolated by precipitation with ammo-
nium sulphate from blood serum of 11 patients with mul-
tiple myeloma. Electrophoretic analysis in the denaturing 
conditions showed that these preparations differ by ratio 
between various subclasses of immunoglobulins. Taking 
into account the molecular weights of human antibody’s 
heavy chains [18], one can suggest that 5 of 11 Abs prepa-
rations are enriched with IgGs (Fig. 1, lines 1, 3, 5, 7, 9), 
2 preparations mainly consist of IgM (Fig. 1, lines 4, 6) 
and 3 other preparation mainly contain IgA (Fig. 1, lines 2, 
10, 11). To analyze proteolytic activity of Igs preparations, 
we used as substrate partly purified linker histone H1 that 
contained considerable amount of core histones (Fig. 2, 
line 12). Electrophoretic analysis showed that 3 of 11 Igs 
preparations obtained from blood serum of patients with 
multiple myeloma, effectively cleaved histone H1 but not 
core histones (Fig. 2, lines 5, 6, 10). This finding suggests 
that blood serum of multiple myeloma patients contains 
catalytically active antibodies hydrolyzing hisH1. 
Validation of proteolytic activity of Abs. To 
prove that the ability of hydrolyzing hisH1 is an intrinsic 
property of antibody molecules following procedures 
were used [19]. 
Important condition for the detection of abzymes is 
the affinity of catalytically active antibodies toward their 
substrates. Since histone H1 served as a substrate for 
protease activity, two catalytically active preparations, 
enriched with IgG and IgM (Fig 2, lines 5, 6), were 
subjected to affinity chromatography on a column 
containing hisH1-Sepharose (Fig. 3, a). Four fractions 
containing proteins bound and unbound to histone H1, 
were obtained and analyzed by PAGE electrophoresis 
(Fig. 3, b). Electroporetic analysis showed that affinity 
isolated fractions of both Ab preparations mainly contain 
IgGs and small amount of others proteins of different 
molecular weight. (Fig. 3, b, lines 1, 2). It should be 
noted that IgM, in contrast to IgG, did not bind histone 
H1-sepharose (Fig. 3, b, line 4). The obtained data 
suggest that proteolytically active Ab preparations, 
isolated by precipitation with ammonium sulfate from 
blood serum of patients with multiple myeloma, contain 
IgG-class antibodies possessing affinity to histone H1. 
Ab fractions were analyzed for histone H1 hydroly-
zing activity (Fig. 3, c). Analysis of proteolytic activity 
revealed that the fractions containing affinity purified 
IgGs effectively cleaved histone H1 (Fig. 3, c, lines 1, 2), 
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in comparison with fractions containing unbound Ab 
where proteolytic activity toward  histone H1 was sig-
nificantly lower (Fig. 3, c, lines 3, 4). Some proteolytic 
activity detected in unbound antibody fractions could 
be explained by specificity of affinity chromatography 
which does not allows a complete one-step isolation of 
proteolytically active abzymes from antibodies pool. On 
the other hand, it is not excluded that some antibodies 
with low histone H1-hydrolyzing activity does not bind 
to affinity column in the presence of 140 mM NaCl. 
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Fig. 1. SDS-electrophoresis of Ig, precipitated from blood serum of 
multiple myeloma patients by 50% sulfate ammonium. Lines 1–11 — 
preparations of Igs. M — molecular weight markers
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Fig. 2. Electrophoretic analysis of proteolytic activity of Igs, 
obtained from blood serum of patients with multiple myeloma 
(lines 1–11). Line 12 — histones before incubation with IgGs 
(control). Position of histone H1 and core histones on the gel 
are enclosed in boxes and shown by arrows. Positin of immu-
noglobulines light chains (L) shown by arrow.
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Fig. 3. Purification of Abs with affinity to histone H1 and analysis of 
their proteolytic activity. a, Affinity chromatography on histone H1-
Sepharose of catalytically active Ig-preparations 5 and 6 (see Fig. 1, 
lines 5, 6). b, Electrophoretic analysis of binding proteins (lines 1, 2) 
and unbound proteins (lines 3, 4). M — molecular weight markers. c, 
Electrophoretic analysis of histone H1 hydrolysis in the presence of 
bound (1, 2) and unbound (3, 4) to histone H1-sepharose proteins. 
K — histone H1 in the absence of proteins
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Fig. 4. Analysis of proteolytic activity of anti-histone H1 IgGs. 
a, Gel filtration of Ab in 0.1 M glycine-HCl buffer (pH 2.6). b, Elec-
trophoretic analysis of products of histone H1 hydrolysis in the 
presence of chromatographic fractions. The arrows indicate po-
sitions of IgG polypeptides (H(γ) — heavy chain; L — light chain) 
and histone H1 on the gel. M — molecular weight markers
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Fig. 5. Influence of anti-histone Н1 AB on growth and survival 
of a human T-leukemia CEM cells
Thus, obtained data suggest that proteolysis of histone 
H1 in the presence of two Ab preparations (see Fig. 2, 
lines 5, 6) is caused by IgG capable of bind histone H1.
Presence of protease activity in the affinity purified 
antibody preparations does not guarantee their abzy-
matic properties. To prove that the ability to hydrolyze 
histone H1 is an intrinsic property of antibody mol-
ecules, another routine procedure — pH-shock analysis 
was used [19]. Catalytically active IgG preparations 
purified on histone H1-Sepharose (see Fig. 3, a), were 
combined and gel filtered at the conditions favorable 
for dissociation of immune complexes (Fig. 4, a) with 
subsequent analysis of chromatographic fractions for 
their ability to hydrolyze histone H1 (Fig. 4, b). The ability 
to hydrolyze hisH1 was detected only in the chromato-
graphic fraction which contained IgGs (Fig 4, b, line 4). 
Absence of proteolytic activity in other chromatographic 
fractions indicates that hisH1-hydrolyzing activity of IgG 
belongs to immunoglobulins rather than to possible 
admixtures of proteases present in blood serum.
Anti-histone H1 Abs impact on cell proliferation. 
Further, we compared the effect of catalytically active 
anti-histone H1 IgG (see Fig. 3, b, line 1) and catalytically 
inactive IgG (Fig. 3, b, line 3) on growth and survival of 
human T-leukemia cells in vitro (Fig. 5). An addition of 
anti-histone H1 IgG to human T-leukemia CEM cells 
significantly increased their time-dependent growth 
compared with action of IgG unbound to histone H1. This 
data demonstrated that anti-histone H1 IgGs isolated 
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from blood serum of patients with multiple myeloma can 
induce proliferation of lymphoid tumor cells.
DISCUSSION
Our data demonstrated that blood serum of 3 of 11 pa-
tients with multiple myeloma similarly to blood serum of 
some patients with multiple sclerosis [14], are capable of 
hydrolyzing calf thymus histone H1 but not cleave core his-
tones. Undoubtedly, these results of the patients’ scree-
ning are preliminary, and further studies are required. 
Data obtained by gel filtration at acidic conditions, 
suggest that this proteolytic activity is an intrinsic 
property of IgGs. The affinity of catalytically active an-
tibodies towards histone H1 allows us to classify them 
as anti-hisH1 autoantibodies [14, 20, 21]. Proteolytic 
ativities of others immunoglobulines (IgM and IgA), 
revealed in antibody preparations, obtained from blood 
serum of patients with multiple myeloma, remains 
unknown and require additional investigation. 
The role of proteolytically active IgGs remains un-
known. Since histone H1 — hydrolyzing IgG of blood 
serum of patients with multiple myeloma belong to anti-
histone H1 auto-Ab, one may speculate that their biologi-
cal activity is similar to activity of anti-histone H1 Ab earlier 
revealed in blood serum of the patients with autoimmune 
diseases. It was shown that anti-histone H1 Ab might play 
an important role in the development of systemic lupus 
erythematosus [22, 23], and be considered as highly 
specific marker of disease progression [24].
According to its antigenic specificity, anti-histone 
H1 Ab could be also classified as antinuclear autoan-
tibody [22–24]. Circulating antinuclear autoantibo-
dies typically found at autoimmune conditions, have 
also been detected in cancer patients and in healthy 
elderly individuals [25]. It was found that antinuclear 
autoantibodies possess a complement-dependent 
and a complement independent toxicity towards dif-
ferent tumor cells [5, 6, 26]. There is a suggestion 
that antinuclear autoantibodies act as antineoplastic 
immune-surveillance agents [25]. 
An intriguing issue of anti-histone H1 Abs activity 
is their influence on the lymphoid cells. It has been 
found that anti-histone H1 Abs modulate tolerogenic 
status of dendritic cells, decrease the cytotoxicity of 
lymphokine-activated killer cells and human natural 
killer cells [27]. Those results suggest that immuno-
suppressive anti-histone H1 Abs decrease cellular 
immune reactivity in patients with multiple myeloma 
towards tumor cells, and in that way they might be 
involved in the disease development.
Our preliminary data show that catalytically active anti-
hisH1 Ab can stimulate proliferation of myeloma cells. We 
suggest that pro-proliferative activity of anti-histone H1 
IgGs is closely linked with biological function of histone 
H1. It is well known that histone H1 is present in the cell 
nucleus where it is involved in process of chromatin rear-
rangement [28, 29]. Recently, we have de monstrated that 
anti-hisH1 Ab isolated from blood serum of multiple scle-
rosis patients was capable to be internali zed by human 
T-leukemia Jurkat cells in vitro [30]. We speculate that 
proliferation of T-leukemia cells is caused by degradation 
of linker histone H1 after internalization of catalytically ac-
tive anti-histone IgGs by the tumor cells and translocation 
of these Ab to the cell nucleus. 
In conclusion, we have shown an existence of previ-
ously unknown histone H1 hydrolyzing IgG abzymes in 
the serum of some multiple myeloma patients. These 
abzymes were isolated and their stimulatory influence on 
human leukemia cells proliferation was demonstrated. 
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